Actively Recruiting
Evaluation of YCANTH VP-102TO-208 Versus Placebo for Treating Common Warts in Children and Adults
Led by Verrica Pharmaceuticals Inc. · Updated on 2026-09-03
300
Participants Needed
20
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
The trial investigates the use of YCANTH VP-102TO-208 for treating common warts in children and adults aged 2 years and older. This Phase 3 study is double-blind, randomized, and vehicle-controlled, aiming to evaluate the safety and effectiveness of YCANTH compared to a placebo vehicle. Common warts caused by the human papilloma virus HPV are the focus, excluding certain wart types and locations. Participants receive topical applications of either YCANTH or a placebo vehicle every 21 days for up to four treatments during a 75-day period. The treated warts are covered with occlusive tape overnight following the application. Treatment may be delayed if temporary local skin reactions occur, and participants must attend all scheduled treatment and follow-up visits regardless of wart clearance. In Japan, participants completing this study may join a long-term follow-up study for up to 54 weeks to monitor safety and efficacy. Participants undergo wart measurements, dermatologic exams, and evaluation of treatment responses during visits. Follow-up includes in-person visits and phone calls to assess clearance and monitor adverse events. Researchers measure the proportion of participants achieving complete wart clearance at Day 84 and monitor safety through adverse event reporting and skin reaction assessments. The total participant involvement spans screening, treatment, and follow-up periods totaling several months.
CONDITIONS
Brief Title
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
Research Team
P
Project Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here